Skip to main content
. Author manuscript; available in PMC: 2019 Feb 6.
Published in final edited form as: Nat Biotechnol. 2018 Jan 10;36(1):46–60. doi: 10.1038/nbt.4017

Figure 2. Integrative sequencing analysis to define the spectrum of cancer aberrations.

Figure 2.

A. Bioinformatic workflow and classes of cancer aberrations identified. The primary sequencing data is subjected to different quality control metrics and aligned to the reference genome to define the indicated genomic and transcriptomic aberrations. B. Prediction of neo-antigens for immunotherapy. The flow chart indicates primary steps involved in in silico prediction of immunogenic cancer specific neo-antigens in tumor samples, for potential use in developing personalized peptide vaccines.